Erste Group Bank Has Bearish Outlook for MRK FY2026 Earnings

Merck & Co., Inc. (NYSE:MRK) – Investment analysts at Erste Group Bank cut their FY2026 earnings per share estimates for Merck & Co., Inc. in a research note issued on Thursday, October 8th. Erste Group Bank analyst H. Engel now anticipates that the company will earn $2.73 per share for the year, down from their previous estimate of $2.75. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $2.66 per share. Erste Group Bank also issued estimates for Merck & Co., Inc.’s FY2027 earnings at $9.47 EPS.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the company earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS.

MRK has been the topic of several other reports. The Goldman Sachs Group increased their price objective on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, August 21st. Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Citigroup boosted their target price on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the company a “neutral” rating in a report on Monday. Jefferies Financial Group upped their price target on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Finally, Wells Fargo & Company upped their price target on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, September 4th. Seventeen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average price target of $151.92.

Merck & Co., Inc. Trading Up 3.9%

NYSE MRK opened at $147.47 on Tuesday. Merck & Co., Inc. has a 12 month low of $82.01 and a 12 month high of $156.92. The company has a 50-day moving average of $144.91 and a 200-day moving average of $128.93. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The company has a market cap of $363.83 billion, a P/E ratio of 117.97, a P/E/G ratio of 6.56 and a beta of 0.21.

Institutional Trading of Merck & Co., Inc.

A number of institutional investors have recently modified their holdings of MRK. Horizons Wealth Management purchased a new position in shares of Merck & Co., Inc. during the 3rd quarter valued at approximately $30,000. Bullseye Investment Management LLC acquired a new stake in shares of Merck & Co., Inc. during the second quarter worth approximately $27,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth $26,000. Graney & King LLC increased its stake in shares of Merck & Co., Inc. by 400.0% in the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after buying an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC acquired a new stake in Merck & Co., Inc. in the second quarter valued at $41,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the sale, the executive vice president owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David Maraldo sold 18,706 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last ninety days. Company insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a $0.85 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Keytruda and pipeline catalysts support Q3 optimism. Continued Keytruda sales growth, expanded indications and newer launches could help Merck exceed third-quarter expectations. Will Keytruda Continue to Aid Merck’s Top Line in Q3 Earnings?
• Positive Sentiment: Oncology pipeline data is an important longer-term catalyst. Merck plans to present first-time pivotal Phase 3 results from three studies and more than 90 additional abstracts at ESMO 2026, potentially providing evidence of growth opportunities as Keytruda eventually faces biosimilar pressure. Merck ESMO 2026 Oncology Pipeline Announcement
• Positive Sentiment: Management sounded constructive on the Moderna cancer vaccine partnership. CEO Rob Davis said manufacturing of the personalized cancer vaccine should become faster and more efficient as Merck and Moderna refine the complex production process. Merck CEO Discusses Cancer Vaccine Manufacturing
• Positive Sentiment: Leerink Partners initiated or reiterated a Buy rating on Merck, adding favorable analyst sentiment. Merck Gets a Buy Rating from Leerink Partners

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.